Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 56

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Coronary artery disease

Not recruiting

Study on the Effect of Influenza Vaccine on Inflammation in Patients with Stable Coronary Artery Disease Using B/Phuket/3073/2013-like Virus and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Granulomatosis with polyangiitis+1

Not recruiting

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Acromegaly

Not recruiting

Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Lymphangioleiomyomatosis

Not recruiting

Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Arterial disorder+1

Not recruiting

Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ever Neuro Pharma GmbH

Multiple system atrophy+1

Not recruiting

Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Exidavnemab
  • Sponsor:BioArctic AB

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

White matter lesion

Not recruiting

Study on the Safety and Tolerability of Guanabenz in Children with Vanishing White Matter Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Guanabenz Acetate
  • Sponsor:Amsterdam UMC Stichting

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Sepsis+1

Not recruiting

Study on Epirubicin and Sodium Chloride for Patients with Sepsis or Septic Shock in Intensive Care Units

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of SPI-62 for Treating ACTH-Dependent Cushing's Syndrome in Patients with Cushing's Disease or Ectopic ACTH/CRH Secretion

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.